CNBC’s Angelica Peebles and Novo Nordisk CEO Lars Fruergaard Jørgensen join 'Squawk Box' to discuss the company's quarterly ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

With me today, I have CEO of Novo Nordisk, Lars Fruergaard Jorgensen; Executive Vice President and Head of Commercial Strategy and Corporate Affairs Camilla Sylvest; Executive Vice President ...

Novo Nordisk beat analyst expectations as it grew sales by 25% in 2024, spearheaded by continued growth for its GLP-1 weight-loss-aiding medications Ozempic and Wegovy. The group’s CEO ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too worried about the upcoming Medicare price negotiations over blockbuster GLP-1 drugs, even though the company still stands with the industry against ...

This is because CEO Lars Jørgensen believes that the prices are already similar to those in Europe. In addition, the company has experience with negotiations since Novo Nordisk has already gone ...

Novo Nordisk closed up 4.5% Wednesday. Shares of obesity drug rival Eli Lilly, meanwhile, rose 1.4%. Speaking to CNBC Wednesday, CEO and President Lars Fruergaard Jørgensen said that the company ...

Consequently, Novo Nordisk's overall turnover and operating profits both expanded by 26 per cent to a record £32billion and £14.3billion, respectively. Lars Fruergaard Jørgensen, president and ...

STORY HIGHLIGHTS Novo Nordisk plans $4.1 billion expansion in Clayton, creating 1,000 jobs. CEO Lars Fruergaard Jørgensen believes potential tariffs can be handled. Analysts expect minimal ...